Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 4 | 2023 | 66 | 1.100 |
Why?
|
| Laser Coagulation | 3 | 2019 | 54 | 0.960 |
Why?
|
| Bevacizumab | 3 | 2019 | 281 | 0.900 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2019 | 311 | 0.820 |
Why?
|
| Fluorescein Angiography | 2 | 2019 | 96 | 0.660 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2018 | 85 | 0.630 |
Why?
|
| Medicare | 1 | 2018 | 410 | 0.520 |
Why?
|
| Cataract | 6 | 2007 | 86 | 0.460 |
Why?
|
| Lens Implantation, Intraocular | 3 | 2002 | 23 | 0.400 |
Why?
|
| Cataract Extraction | 4 | 2007 | 31 | 0.370 |
Why?
|
| Aphakia, Postcataract | 2 | 1999 | 4 | 0.350 |
Why?
|
| Visual Acuity | 7 | 2008 | 194 | 0.290 |
Why?
|
| Infant | 13 | 2019 | 3046 | 0.270 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2903 | 0.250 |
Why?
|
| Lens Capsule, Crystalline | 2 | 2002 | 11 | 0.240 |
Why?
|
| Intravitreal Injections | 2 | 2019 | 67 | 0.200 |
Why?
|
| Retrospective Studies | 9 | 2019 | 8489 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 4 | 1995 | 36 | 0.190 |
Why?
|
| Child, Preschool | 15 | 2019 | 3612 | 0.180 |
Why?
|
| Cranial Nerve Neoplasms | 3 | 1995 | 12 | 0.180 |
Why?
|
| Optic Nerve Diseases | 3 | 1995 | 18 | 0.180 |
Why?
|
| Carboplatin | 2 | 2018 | 286 | 0.170 |
Why?
|
| Barotrauma | 1 | 1999 | 5 | 0.170 |
Why?
|
| Play and Playthings | 1 | 1999 | 7 | 0.170 |
Why?
|
| Eye Injuries | 1 | 1999 | 15 | 0.170 |
Why?
|
| Contact Lenses, Extended-Wear | 1 | 1998 | 2 | 0.170 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1999 | 92 | 0.160 |
Why?
|
| SEER Program | 1 | 2018 | 190 | 0.160 |
Why?
|
| Retinal Neoplasms | 2 | 2008 | 10 | 0.160 |
Why?
|
| Retinoblastoma | 2 | 2008 | 28 | 0.160 |
Why?
|
| Lens Diseases | 1 | 2017 | 2 | 0.160 |
Why?
|
| Eye Infections, Fungal | 1 | 2017 | 14 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 2 | 2007 | 252 | 0.150 |
Why?
|
| Candida albicans | 1 | 2017 | 32 | 0.150 |
Why?
|
| Endophthalmitis | 1 | 2017 | 21 | 0.150 |
Why?
|
| Candidiasis | 1 | 2017 | 36 | 0.150 |
Why?
|
| Abscess | 1 | 2017 | 91 | 0.150 |
Why?
|
| Paclitaxel | 1 | 2018 | 460 | 0.150 |
Why?
|
| Lens, Crystalline | 1 | 2017 | 69 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 455 | 0.140 |
Why?
|
| Incidence | 2 | 2018 | 1577 | 0.140 |
Why?
|
| Recurrence | 1 | 2018 | 1139 | 0.130 |
Why?
|
| Female | 17 | 2019 | 44532 | 0.130 |
Why?
|
| Infant, Newborn | 6 | 2023 | 2379 | 0.130 |
Why?
|
| Humans | 26 | 2023 | 86643 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 2438 | 0.120 |
Why?
|
| Infant, Premature | 3 | 2023 | 290 | 0.120 |
Why?
|
| Child | 12 | 2007 | 6927 | 0.120 |
Why?
|
| Eye | 2 | 1984 | 111 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2018 | 2767 | 0.120 |
Why?
|
| Facial Muscles | 1 | 2013 | 23 | 0.110 |
Why?
|
| Eyelids | 1 | 2013 | 23 | 0.110 |
Why?
|
| Oculomotor Muscles | 1 | 2013 | 28 | 0.110 |
Why?
|
| Tendons | 1 | 2013 | 44 | 0.110 |
Why?
|
| Optic Chiasm | 1 | 1992 | 16 | 0.110 |
Why?
|
| Neurilemmoma | 1 | 1992 | 34 | 0.110 |
Why?
|
| Male | 14 | 2019 | 40965 | 0.090 |
Why?
|
| Microphthalmos | 1 | 2008 | 7 | 0.080 |
Why?
|
| Skin Abnormalities | 1 | 2008 | 11 | 0.080 |
Why?
|
| Limb Deformities, Congenital | 1 | 2008 | 21 | 0.080 |
Why?
|
| Laser Therapy | 2 | 2008 | 142 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2008 | 29 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6509 | 0.080 |
Why?
|
| Refraction, Ocular | 2 | 2019 | 9 | 0.080 |
Why?
|
| Podophyllotoxin | 1 | 2007 | 10 | 0.080 |
Why?
|
| Toxoplasmosis, Congenital | 1 | 2007 | 42 | 0.080 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2007 | 27 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 100 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2008 | 73 | 0.080 |
Why?
|
| Adolescent | 10 | 2008 | 8981 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 232 | 0.070 |
Why?
|
| Amblyopia | 1 | 2006 | 7 | 0.070 |
Why?
|
| Sensory Deprivation | 1 | 2006 | 31 | 0.070 |
Why?
|
| Eyeglasses | 1 | 2006 | 8 | 0.070 |
Why?
|
| United States | 1 | 2018 | 6672 | 0.070 |
Why?
|
| Vitrectomy | 3 | 2003 | 52 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 276 | 0.070 |
Why?
|
| Eye Diseases | 1 | 1984 | 53 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 639 | 0.060 |
Why?
|
| Vision Tests | 1 | 1983 | 20 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 18415 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 1984 | 151 | 0.060 |
Why?
|
| Vision, Ocular | 1 | 1983 | 71 | 0.060 |
Why?
|
| Retinal Detachment | 1 | 2003 | 66 | 0.060 |
Why?
|
| Skin Diseases | 1 | 1984 | 166 | 0.060 |
Why?
|
| Pseudophakia | 2 | 2002 | 3 | 0.050 |
Why?
|
| Gestational Age | 1 | 2023 | 311 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2007 | 763 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 407 | 0.050 |
Why?
|
| Iris Diseases | 1 | 1999 | 6 | 0.050 |
Why?
|
| Marfan Syndrome | 1 | 1999 | 28 | 0.040 |
Why?
|
| Corneal Diseases | 1 | 1999 | 32 | 0.040 |
Why?
|
| Vision, Low | 1 | 2019 | 15 | 0.040 |
Why?
|
| Administration, Ophthalmic | 1 | 2019 | 9 | 0.040 |
Why?
|
| Hearing Loss | 1 | 2019 | 56 | 0.040 |
Why?
|
| Cerebral Palsy | 1 | 2019 | 90 | 0.040 |
Why?
|
| Vision, Binocular | 1 | 1998 | 20 | 0.040 |
Why?
|
| Risk Factors | 3 | 2023 | 5417 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 5210 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2002 | 3640 | 0.040 |
Why?
|
| Recovery of Function | 1 | 1999 | 272 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 678 | 0.040 |
Why?
|
| Infant, Premature, Diseases | 1 | 2017 | 78 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2017 | 117 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2008 | 7993 | 0.040 |
Why?
|
| Lenses, Intraocular | 1 | 1995 | 12 | 0.030 |
Why?
|
| Syndrome | 2 | 2008 | 446 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 1995 | 54 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1995 | 82 | 0.030 |
Why?
|
| Age Factors | 4 | 2006 | 1851 | 0.030 |
Why?
|
| Blepharoptosis | 1 | 2013 | 11 | 0.030 |
Why?
|
| Fasciotomy | 1 | 2013 | 16 | 0.030 |
Why?
|
| Theophylline | 1 | 1993 | 34 | 0.030 |
Why?
|
| Cadaver | 1 | 2013 | 185 | 0.030 |
Why?
|
| Glioma | 1 | 1994 | 285 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1686 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2008 | 6 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 55 | 0.020 |
Why?
|
| Pyrimethamine | 1 | 2007 | 21 | 0.020 |
Why?
|
| Adult | 5 | 2007 | 25648 | 0.020 |
Why?
|
| Sulfadiazine | 1 | 2007 | 24 | 0.020 |
Why?
|
| Blindness | 1 | 2008 | 41 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 894 | 0.020 |
Why?
|
| Antiprotozoal Agents | 1 | 2007 | 33 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 218 | 0.020 |
Why?
|
| Etoposide | 1 | 2008 | 196 | 0.020 |
Why?
|
| Ataxia Telangiectasia | 1 | 1984 | 11 | 0.020 |
Why?
|
| Sturge-Weber Syndrome | 1 | 1984 | 8 | 0.020 |
Why?
|
| Pigmentation Disorders | 1 | 1984 | 13 | 0.020 |
Why?
|
| Tuberous Sclerosis | 1 | 1984 | 28 | 0.020 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1984 | 17 | 0.020 |
Why?
|
| Asthma | 1 | 1993 | 955 | 0.020 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 5 | 0.020 |
Why?
|
| Dapsone | 1 | 1984 | 10 | 0.020 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1984 | 18 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2008 | 4213 | 0.020 |
Why?
|
| Ocular Physiological Phenomena | 1 | 1983 | 11 | 0.020 |
Why?
|
| Strabismus | 1 | 1983 | 10 | 0.020 |
Why?
|
| Prednisone | 1 | 1984 | 258 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2007 | 814 | 0.010 |
Why?
|
| Cats | 1 | 1983 | 303 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 1531 | 0.010 |
Why?
|
| Evoked Potentials, Visual | 1 | 1983 | 87 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1983 | 510 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1992 | 2601 | 0.010 |
Why?
|
| Child Development | 1 | 1983 | 163 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1313 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 152 | 0.010 |
Why?
|
| Visual Cortex | 1 | 1983 | 251 | 0.010 |
Why?
|
| Visual Perception | 1 | 1983 | 319 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 3362 | 0.010 |
Why?
|
| Miotics | 1 | 1999 | 1 | 0.010 |
Why?
|
| Pilocarpine | 1 | 1999 | 7 | 0.010 |
Why?
|
| Corneal Edema | 1 | 1999 | 6 | 0.010 |
Why?
|
| Aging | 1 | 1983 | 691 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1983 | 2232 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 364 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1993 | 121 | 0.010 |
Why?
|
| Body Temperature | 1 | 1993 | 124 | 0.010 |
Why?
|
| Respiratory Tract Infections | 1 | 1993 | 105 | 0.010 |
Why?
|
| Fever | 1 | 1993 | 125 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 429 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1993 | 916 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1994 | 1019 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 912 | 0.010 |
Why?
|
| Epiglottis | 1 | 1984 | 6 | 0.000 |
Why?
|
| Complement C3 | 1 | 1984 | 58 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1984 | 83 | 0.000 |
Why?
|
| Animals | 1 | 1983 | 26582 | 0.000 |
Why?
|
| Basement Membrane | 1 | 1984 | 54 | 0.000 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1984 | 316 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1984 | 456 | 0.000 |
Why?
|
| Radiography | 1 | 1984 | 813 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1984 | 1565 | 0.000 |
Why?
|
| Middle Aged | 1 | 1984 | 25028 | 0.000 |
Why?
|